ストックスクリーナーアプリを入手
7.07
1.74%
-0.11
前日終値:
$7.18
開ける：
$7.15
24時間の取引高:
801.08K
Relative Volume:
0.14
時価総額：
$1.83B
収益：
$6.28B
当期純損益:
$700.00M
株価収益率:
2.6261
EPS:
2.6922
ネットキャッシュフロー:
$537.00M
1週間 パフォーマンス:
+1.07%
1か月 パフォーマンス:
-8.50%
6か月 パフォーマンス:
-28.45%
1年 パフォーマンス:
-53.15%
1日の値動き範囲:
$7.035
$7.15
1週間の範囲:
$6.97
$7.21
52週間の値動き範囲:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
OGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.0544 | 1.87B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,083.70 | 964.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
209.18 | 500.24B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
231.20 | 406.46B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
139.17 | 267.06B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
107.09 | 265.03B | 63.90B | 19.05B | 13.05B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-10-27 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Does Organon’s 50% Share Price Slide Signal Opportunity in 2025? - Yahoo Finance
Gilman Hill Asset Management LLC Reduces Position in Organon & Co. $OGN - MarketBeat
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com
Why (OGN) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Organon: Deep Value With No Clear Catalysts (NYSE:OGN) - Seeking Alpha
Pharma co Organon inks VPPA with Schneider Electric for solar in Spain - Renewables Now
Securities Lawsuit Alert: Organon & Co. (OGN)Contact Levi & Korsinsky Before July 22, 2025 - TMX Newsfile
Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Organon pushes for sustainable investment in women’s health across Africa - The Business & Financial Times
TetraScience and Organon Collaborate to Modernize Quality Control Data Management - 富途牛牛
Organon Launches Phase 3 Study on Tapinarof Cream for Atopic Dermatitis in Infants - TipRanks
How Investors Are Reacting To Organon (OGN) As Barclays Joins Growing Analyst Skepticism - Sahm
Why Analysts See Organon’s Story Shifting Amid Governance Concerns And Lower Valuations - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon & Co. $OGN Stake Lessened by Globeflex Capital L P - MarketBeat
Organon Shares Under Pressure Following Critical Analyst Review - AD HOC NEWS
Can Organon’s Steep 2025 Share Price Slide Signal a Long Term Opportunity? - simplywall.st
Organon pushes bold women’s health agenda at WHX Leaders’ Summit in Accra - MyJoyOnline
Les billets sont maintenant en vente pour Importance Vitale : sommet national sur la santé des femmes - GlobeNewswire Inc.
Why Organon (OGN) shares are trading lower today - MSN
New York State Common Retirement Fund Sells 353,330 Shares of Organon & Co. $OGN - MarketBeat
Understanding Momentum Shifts in (OGN) - news.stocktradersdaily.com
Investors in Organon & Co. (OGN): Protect Your RightsContact Levi & Korsinsky Before July 22, 2025 - ACCESS Newswire
Organon & Co. (NYSE:OGN) Stock Rating Upgraded by Barclays - MarketBeat
Organon & Co. $OGN Shares Bought by Cerity Partners LLC - MarketBeat
WHX Africa Leaders Summit: Organon Unveils Multi-Sector Approach to Women’s Health in Africa - News Ghana
Barclays Initiates Coverage of Organon (OGN) with Underweight Recommendation - Nasdaq
Why Organon (OGN) Shares Are Trading Lower Today - Finviz
Organon (OGN) Receives New Coverage with 'Underweight' Rating fr - GuruFocus
Barclays Initiates Coverage on Organon & Co. (NYSE:OGN) - MarketBeat
Norges Bank Takes $19.78 Million Position in Organon & Co. $OGN - MarketBeat
Organon initiated with an Underweight at Barclays - TipRanks
American Century Companies Inc. Grows Position in Organon & Co. $OGN - MarketBeat
What analysts say about Organon Co stockFederal Reserve Announcements & Outstanding Growth Strategies - earlytimes.in
A Closer Look At Organon & Co.'s (NYSE:OGN) Impressive ROE - 富途牛牛
Can Organon (OGN) Turn Rising Investor Attention Into a Durable Reboot of Its Core Story? - simplywall.st
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Co. (7XP) stock compared to peersPortfolio Update Report & Precise Buy Zone Identification - Newser
Organon & Co. $OGN Shares Acquired by Brandes Investment Partners LP - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Russell Investments Group Ltd. Has $15.96 Million Stock Position in Organon & Co. $OGN - MarketBeat
Can Organon’s (OGN) Biosimilar Push Transform Its Competitive Position in US Oncology? - Yahoo Finance
A Look at Organon's Valuation Following FDA Approval of First US Pertuzumab Biosimilar - Yahoo Finance
Is Organon’s Recent 14% Price Jump Justified After Women’s Health Partnership News? - Yahoo Finance
What analysts say about Organon Co 7XP stockShort Interest Overview & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings? - The Globe and Mail
Grantham Mayo Van Otterloo & Co. LLC Buys 108,429 Shares of Organon & Co. $OGN - MarketBeat
Avoiding Lag: Real-Time Signals in (OGN) Movement - news.stocktradersdaily.com
Organon (OGN): Exploring Valuation Following FDA Approval of First US Pertuzumab Biosimilar - simplywall.st
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
0.36%
大文字化:
|
ボリューム (24 時間):